STOCK TITAN

Singular Genomics Systems, Inc. - OMIC STOCK NEWS

Welcome to our dedicated page for Singular Genomics Systems news (Ticker: OMIC), a resource for investors and traders seeking the latest updates and insights on Singular Genomics Systems stock.

Singular Genomics Systems, Inc. is a pioneering life science technology company headquartered in La Jolla, California. Positioned in the heart of the biotech hub near the Pacific Ocean, Singular Genomics is surrounded by prestigious institutions such as the Salk Institute, Scripps, Sanford Burnham, and UCSD. The company is at the cutting edge of genomics, one of the world's fastest-growing industries, and boasts a dynamic and fast-paced work environment that encourages innovation and results.

Singular Genomics is committed to advancing science and medicine through the development of next-generation sequencing (NGS) and multiomics technologies. Their product portfolio includes the G4 Sequencing Platform and the PX Integrated Solution, each designed to cater to distinct market needs. The G4 Sequencing Platform targets the NGS market, while the PX Integrated Solution focuses on single-cell, spatial analysis, and proteomics markets. These products are applicable in diverse fields such as oncology, immunology, neurology, genetic diseases, infectious diseases, and the human microbiome.

The company also recently introduced the G4X™ Spatial Sequencer, a high-throughput in situ spatial sequencing platform capable of direct RNA sequencing, targeted transcriptomics, proteomics, and fluorescent H&E staining from formalin-fixed, paraffin-embedded (FFPE) tissues. This upgrade to the G4 Sequencing Platform marks Singular Genomics as the only company worldwide to offer capabilities for tissue-based in situ spatial multiomics and NGS on the same instrument.

Singular Genomics prides itself on its strong culture of collaboration and innovation. The company offers competitive benefits, including free gym memberships, a 401k plan, flexible vacation policies, and equity incentives, allowing employees to grow alongside the company. The firm’s mission is to empower researchers and clinicians to advance science and medicine, driving forward the potential of genomics to improve human health.

In recent developments, Singular Genomics' management participated in a panel discussion titled “Emerging Life Science Technologies Across Genomics and Proteomics.” This event highlighted their ongoing commitment to innovation and collaboration within the field. The company continues to make significant strides with the G4X system, which promises unprecedented throughput and capabilities for spatial profiling of tissue, further cementing its role as a leader in genomics technology.

Rhea-AI Summary

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company specializing in next-generation sequencing and spatial multiomics technologies, has received an unsolicited non-binding acquisition proposal from Concentra Biosciences, The offer is to acquire all outstanding shares of Singular Genomics for $12.00 per share in cash. Alternatively, Concentra proposed offering a contingent value right for interested stockholders to participate in future value realization.

Tang Capital, the controlling stockholder of Concentra, owns approximately 14.9% of Singular Genomics' outstanding common stock. The company's board has previously formed a special committee of independent directors to evaluate strategic alternatives, including this proposal. TD Cowen is serving as the financial advisor to the special committee.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
-
Rhea-AI Summary

Singular Genomics Systems (Nasdaq: OMIC) has received a non-binding acquisition proposal from Deerfield Management Company and affiliated funds. The offer is to acquire all outstanding shares not already owned by Deerfield for $10.00 per share in cash. Deerfield, an existing stockholder, plans to invite other major stockholders and management to rollover their shares into the new company.

A special committee of independent directors, previously formed to evaluate strategic alternatives, will consider this proposal. The company emphasizes that there's no assurance of any transaction being consummated. TD Cowen is serving as the financial advisor to the special committee, with legal advisors also appointed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
119.12%
Tags
-
Rhea-AI Summary

Singular Genomics Systems (Nasdaq: OMIC) reported Q2 2024 financial results and recent highlights. The company recognized revenue of $0.7 million, shipped 2 G4 systems, and advanced development of the G4X Spatial Sequencer. Key financial metrics include:

- Gross profit: -$0.2 million
- Operating expenses: $22.6 million
- Net loss: $21.3 million (-$8.57 per share)
- Cash, equivalents, and short-term investments: $133.2 million

The company launched a Spatial Sequencing Technology Access Services program and opened a Spatial Research Grant award program. Singular Genomics also amended a long-term lease obligation, reducing obligations by approximately $50 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Singular Genomics Systems (Nasdaq: OMIC), a company specializing in next-generation sequencing (NGS) and spatial multiomics technologies, has announced its plans to report second quarter 2024 financial results on August 13, 2024, after market close. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results.

Investors can join the call by dialing 1-888-506-0062 (domestic) or 1-973-528-0011 (international) using conference ID 661035. A live and archived webcast will be available on the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
conferences earnings
-
Rhea-AI Summary

Singular Genomics Systems (Nasdaq: OMIC), a company specializing in next-generation sequencing (NGS) and spatial multiomics technologies, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company had previously received a non-compliance notice on July 17, 2023, as its stock price had fallen below $1.00 for 30 consecutive business days.

To meet the compliance standards, OMIC's closing bid price remained at or above $1.00 for 11 consecutive trading days from June 26 to July 11, 2024. This achievement ensures Singular Genomics' continued listing on the Nasdaq Capital Market, resolving the previous compliance issue.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.58%
Tags
none
-
Rhea-AI Summary

Singular Genomics Systems (Nasdaq: OMIC) announced a 1-for-30 reverse stock split effective June 26, 2024, at 12:01 a.m. Eastern Time. The company's common stock will trade on a split-adjusted basis under the current symbol 'OMIC'. The new CUSIP number will be 82933R 308. This move aims to regain compliance with Nasdaq's minimum bid price requirement. Approved by stockholders on May 29, 2024, the split will convert 30 existing shares into one new share, reducing outstanding shares from 74.7 million to approximately 2.5 million. Authorized shares remain at 400 million, and the par value stays at $0.0001 per share. No fractional shares will be issued; instead, they will be rounded up to the nearest whole share. The reverse split does not affect Series A Preferred Stock or the proportional conversion ratio. Continental Stock Transfer & Trust Company will manage the exchange, with stockholders receiving information regarding their adjusted holdings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.29%
Tags
Rhea-AI Summary

Singular Genomics Systems (Nasdaq: OMIC) will present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, Florida. The presentation is scheduled for Wednesday, June 12, 2024, at 7:40 a.m. PT / 10:40 a.m. ET. Management will participate in a fireside chat, and a live and recorded webcast will be available at investor.singulargenomics.com. Singular Genomics leverages novel next-generation sequencing (NGS) and spatial multiomics technologies to support researchers and clinicians.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
conferences
-
Rhea-AI Summary

Singular Genomics (Nasdaq: OMIC) reported its Q1 2024 financial results and highlighted recent achievements. Revenue for the quarter stood at $0.4 million, primarily from one G4 instrument sale and consumables. The company shipped six G4 systems, totaling 30 commercial units. Gross profit was negative $0.4 million, and operating expenses were $26.4 million, leading to a net loss of $25.0 million ($0.34 per share). Singular Genomics aims to launch its G4X spatial sequencer in 2025 and continues to support its existing customer base and expand its spatial services.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.63%
Tags
-
Rhea-AI Summary

Singular Genomics Systems, Inc. (Nasdaq: OMIC) will announce its first quarter 2024 financial results on May 14, 2024, after the market closes. The company focuses on next-generation sequencing and spatial multiomics technologies. The management will host a conference call to discuss the results. Investors can join the call or access the webcast on investor.singulargenomics.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
conferences earnings
Rhea-AI Summary
Singular Genomics Systems, Inc. (Nasdaq: OMIC) reported strong financial results for the fourth quarter and full year ended December 31, 2023. The company generated revenue of $1.1 million in Q4 2023, representing a 41% growth compared to the prior year. They shipped eight G4 systems in Q4, bringing the total to 24 commercial systems. Singular Genomics unveiled the G4X Spatial Sequencer, offering high-throughput in situ spatial sequencing capabilities. The G4X is expected to enhance sample throughput, reduce turnaround time, and lower costs. The company also announced updates to the G4 benchtop sequencing system and showcased Singular Connect, a web-based application for real-time monitoring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.03%
Tags

FAQ

What is the current stock price of Singular Genomics Systems (OMIC)?

The current stock price of Singular Genomics Systems (OMIC) is $13.48 as of October 4, 2024.

What is the market cap of Singular Genomics Systems (OMIC)?

The market cap of Singular Genomics Systems (OMIC) is approximately 36.8M.

What does Singular Genomics Systems, Inc. do?

Singular Genomics Systems, Inc. develops next-generation sequencing and multiomics technologies to empower researchers and clinicians in advancing science and medicine.

Where is Singular Genomics Systems, Inc. located?

The company is headquartered in La Jolla, California, within the biotech hub near the Pacific Ocean.

What are some of the key products offered by Singular Genomics?

Singular Genomics offers the G4 Sequencing Platform and the PX Integrated Solution, targeting NGS and single-cell, spatial analysis, and proteomics markets, respectively.

What is the G4X™ Spatial Sequencer?

The G4X™ Spatial Sequencer is a high-throughput in situ spatial sequencing platform capable of direct RNA sequencing, targeted transcriptomics, proteomics, and fluorescent H&E staining.

What markets do Singular Genomics' products serve?

Their products serve various markets, including oncology, immunology, neurology, genetic diseases, infectious diseases, and the human microbiome.

What are some benefits offered to employees at Singular Genomics?

Employees enjoy benefits such as free gym memberships, a 401k plan, competitive health benefits, flexible vacation policies, and equity incentives.

What recent event did Singular Genomics' management participate in?

They participated in a panel discussion titled 'Emerging Life Science Technologies Across Genomics and Proteomics,' highlighting their ongoing commitment to innovation.

How is Singular Genomics contributing to scientific advancements?

By developing cutting-edge sequencing technologies and collaborating with leading institutions, Singular Genomics accelerates research and discovery in various scientific fields.

What makes the G4X system unique?

The G4X system offers unprecedented throughput and the ability to perform in situ spatial multiomics and NGS on the same instrument, positioning Singular Genomics as an industry leader.

Where can investors find more information about Singular Genomics?

Investors can visit Singular Genomics’ official website at www.singulargenomics.com or contact their investor relations team for more information.

Singular Genomics Systems, Inc.

Nasdaq:OMIC

OMIC Rankings

OMIC Stock Data

36.81M
2.50M
13.9%
41.23%
0.57%
Medical Instruments & Supplies
Laboratory Analytical Instruments
Link
United States of America
SAN DIEGO